Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 May;109(1):113–119. doi: 10.1111/j.1476-5381.1993.tb13539.x

Calcium antagonistic and antiarrhythmic actions of CPU-23, a substituted tetrahydroisoquinoline.

H Dong 1, J Z Sheng 1, C M Lee 1, T M Wong 1
PMCID: PMC2175576  PMID: 8495235

Abstract

1. The effects of CPU-23 (1-(1-[(6-methoxyl)-naphth-2-yl])-propyl-2-(1-piperidine)-acetyl-6 ,7- dimethyoxy-1,2,3,4-tetra-hydroisoquinoline) were studied on mechanical and electrical activities, and intracellular free calcium ([Ca2+]i) of isolated cardiac tissues in order to investigate its spectrum and mechanisms of action in the heart. Its antiarrhythmic and haemodynamic effects in pentobarbitone-anaesthetized rats subjected to coronary artery ligation were also evaluated. 2. CPU-23 at 10(-6)-10(-4) M markedly inhibited slow action potential characteristics in guinea-pig papillary muscles and pace-maker action potential of rabbit sinoatrial node. It affected fast action potential only at 10(-4) M. None of the effects of CPU-23 was reversed by washout for up to 2 h. 3. Like nifedipine and diltiazem, CPU-23 decreased the heart rate of the isolated perfused heart of the rat. However, in contrast to these two classical calcium antagonists which dose-dependently inhibited the force of contraction, CPU-23 inhibited and stimulated the force of contraction at 10(-7)-3 x 10(-6) M and 10(-5) M, respectively. 4. CPU-23 at 10(-6)-10(-5) M inhibited the KCl-induced [Ca2+]i increase in the Ca2+ medium, but did not affect the caffeine-induced [Ca2+]i increase in the Ca(2+)-free medium in isolated ventricular myocytes. 5. CPU-23 at 1-5 mg kg-1 reduced dose-dependently ventricular arrhythmias including ventricular ectopic beats, VT and VF as well as mortality during coronary artery ligation. At 2.5-5 mg kg-1 it even abolished VF, which was accompanied by 100% survival.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
113

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Au T. L., Curtis M. J., Walker M. J. Effects of (-), (+/- ), and (+) verapamil on coronary occlusion-induced mortality and infarct size. J Cardiovasc Pharmacol. 1987 Sep;10(3):327–331. doi: 10.1097/00005344-198709000-00012. [DOI] [PubMed] [Google Scholar]
  2. Clark C., Foreman M. I., Kane K. A., McDonald F. M., Parratt J. R. Coronary artery ligation in anesthetized rats as a method for the production of experimental dysrhythmias and for the determination of infarct size. J Pharmacol Methods. 1980 Jun;3(4):357–368. doi: 10.1016/0160-5402(80)90077-7. [DOI] [PubMed] [Google Scholar]
  3. Conti C. R., Pepine C. J., Feldman R. L., Hill J. A. Calcium antagonists. Cardiology. 1985;72(5-6):297–321. doi: 10.1159/000173886. [DOI] [PubMed] [Google Scholar]
  4. Curtis M. J., MacLeod B. A., Walker M. J. Antiarrhythmic actions of verapamil against ischaemic arrhythmias in the rat. Br J Pharmacol. 1984 Oct;83(2):373–385. doi: 10.1111/j.1476-5381.1984.tb16497.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Curtis M. J., Walker M. J. The mechanism of action of calcium antagonists on arrhythmias in early myocardial ischaemia: studies with nifedipine and DHM9. Br J Pharmacol. 1988 Aug;94(4):1275–1286. doi: 10.1111/j.1476-5381.1988.tb11648.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Curtis M. J., Walker M. J. The mechanism of action of the optical enantiomers of verapamil against ischaemia-induced arrhythmias in the conscious rat. Br J Pharmacol. 1986 Sep;89(1):137–147. doi: 10.1111/j.1476-5381.1986.tb11129.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dong H., Lee C. M., Huang W. L., Peng S. X. Cardiovascular effects of substituted tetrahydroisoquinolines in rats. Br J Pharmacol. 1992 Sep;107(1):262–268. doi: 10.1111/j.1476-5381.1992.tb14496.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fagbemi O., Parratt J. R. Calcium antagonists prevent early post-infarction ventricular fibrillation. Eur J Pharmacol. 1981 Nov 5;75(4):179–185. doi: 10.1016/0014-2999(81)90543-4. [DOI] [PubMed] [Google Scholar]
  9. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977;17:149–166. doi: 10.1146/annurev.pa.17.040177.001053. [DOI] [PubMed] [Google Scholar]
  10. Freedman D. D., Waters D. D. 'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications. Drugs. 1987 Nov;34(5):578–598. doi: 10.2165/00003495-198734050-00005. [DOI] [PubMed] [Google Scholar]
  11. Grynkiewicz G., Poenie M., Tsien R. Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985 Mar 25;260(6):3440–3450. [PubMed] [Google Scholar]
  12. Huang W. L., Song X. Q., Peng S. X., Huang Z. Y. [The synthesis and biological activity of substituted tetrahydroisoquinoline compounds]. Yao Xue Xue Bao. 1990;25(11):815–823. [PubMed] [Google Scholar]
  13. Huang X. D., Wong T. M. Morphine and (D-Ala2, NMe-Phe4, Gly-ol)-enkephalin increase the intracellular free calcium in isolated rat myocytes--effect of naloxone or pretreatment with morphine. Life Sci. 1991;48(11):1101–1107. doi: 10.1016/0024-3205(91)90512-a. [DOI] [PubMed] [Google Scholar]
  14. Ledda F., Mantelli L., Mugelli A. Blockade by burimamide of the restorative effect of histamine in tetrodotoxin-treated heart preparations. Br J Pharmacol. 1976 Jun;57(2):247–249. doi: 10.1111/j.1476-5381.1976.tb07474.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ledda F., Mantelli L., Mugelli A. alpha-Sympathomimetic amines and calcium-mediated action potentials in guinea-pig ventricular muscle. Br J Pharmacol. 1980 Aug;69(4):565–571. doi: 10.1111/j.1476-5381.1980.tb07905.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Malécot C. O., Trautwein W. On the relationship between V max of slow responses and Ca-current availability in whole-cell clamped guinea pig heart cells. Pflugers Arch. 1987 Sep;410(1-2):15–22. doi: 10.1007/BF00581890. [DOI] [PubMed] [Google Scholar]
  17. Merillat J. C., Lakatta E. G., Hano O., Guarnieri T. Role of calcium and the calcium channel in the initiation and maintenance of ventricular fibrillation. Circ Res. 1990 Nov;67(5):1115–1123. doi: 10.1161/01.res.67.5.1115. [DOI] [PubMed] [Google Scholar]
  18. Mugelli A., Amerini S., De Bonfioli Cavalcabo P., Cerbai E., Visentin S. Electrophysiological effects mediated by the stimulation of cardiac beta 2-adrenoceptors with tulobuterol. Cardiovasc Drugs Ther. 1987;1(1):101–107. doi: 10.1007/BF02125839. [DOI] [PubMed] [Google Scholar]
  19. Ohtsuka M., Yokota M., Kodama I., Yamada K., Shibata S. New generation dihydropyridine calcium entry blockers: in search of greater selectivity for one tissue subtype. Gen Pharmacol. 1989;20(5):539–556. doi: 10.1016/0306-3623(89)90084-0. [DOI] [PubMed] [Google Scholar]
  20. Opthof T., de Jonge B., Mackaay A. J., Bleeker W. K., Masson-Pevet M., Jongsma H. J., Bouman L. N. Functional and morphological organization of the guinea-pig sinoatrial node compared with the rabbit sinoatrial node. J Mol Cell Cardiol. 1985 Jun;17(6):549–564. doi: 10.1016/s0022-2828(85)80024-9. [DOI] [PubMed] [Google Scholar]
  21. SELYE H., BAJUSZ E., GRASSO S., MENDELL P. Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology. 1960 Oct;11:398–407. doi: 10.1177/000331976001100505. [DOI] [PubMed] [Google Scholar]
  22. Smith H. J., Singh B. N., Nisbet H. D., Norris R. M. Effects of verapamil on infarct size following experimental coronary occlusion. Cardiovasc Res. 1975 Jul;9(4):569–578. doi: 10.1093/cvr/9.4.569. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES